metrologically traceable. A recovery study, where this standard is added to a base matrix in linearly related concentrations and these samples assayed in the same run, is therefore essential.Why was this not considered worth including?
Secondly, an evaluation should ideally include a split sample comparison over a range of analyte values between the ¢eld method and (1) the reference method for the analyte, to assess speci¢city and calibration; and/or (2) other ¢eld methods, to assess comparability. If there is no reference method, how can we be sure (especially in the absence of a recovery study) that the numerical results have any meaning? If there are no other ¢eld methods, then a more thorough evaluation of the only one in existence is surely essential. Some comment is required on why these elements are missing.
Thirdly, an evaluation should ideally include some recent external quality assurance (EQA) data on within-method, between-laboratory comparability, as well as data on between-method comparability (the Medicines and Healthcare products RegulatoryAgency [MHRA] 2 evaluations do this). EQA data are the only source of independent, objective assessment of ¢eld methods in regular use by clinical laboratories. Why were data from the UK NEQAS service for NTproBNP not included or commented upon?
Without these essential elements, we cannot conclude from this study whether NTproBNP is being measured with the appropriate trueness and traceability that the stated SI unitage requires.
Why is this so important? One reason is that published guidelines for this analyte with 'hard' clinical decision points, probably stated with no indication of measurement uncertainty, will be latched onto by clinicians and then ¢nd their way into national treatment protocols. If new methods are subsequently devised with improved trueness, which yield di¡erent numerical values, there will be problems of interpretation and clinical confusion.
All assays used in clinical laboratories should have optimal trueness, imprecision, reproducibility, robustness and working range, so that they possess the minimum measurement uncertainty appropriate to each clinical application. Formal evaluations of methods must adhere to protocols that are strictly enforced by editors and referees, so that they properly explore these characteristics and yield meaningful conclusions. By analogy with the STARD initiative 3 for studies of diagnostic accuracy, we should be employing universally agreed protocols for method evaluations. I do not forget, of course, that National Council for Clinical Laboratory Standards (NCCLS) 4 have a library of evaluation protocols which are widely used by the diagnostic industry and MHRA. 
Authors' reply
Thank you for allowing us to reply to the comments raised by Dr Jonathan Middle. The NTproBNP method used in our paper has been standardized against synthetic NTproBNP in a human serum matrix 1 and should therefore be a homogeneous molecule, quanti¢able in mass units. New methods for NTproBNP which yield di¡erent numerical values will be unlikely due to the licensing agreement for NTproBNP, so there should not be any clinical confusion over result interpretation.
There is no reference method or any other ¢eld method with which to compare the Elecsyst NTproBNP method, only in-house assays. The NTproBNP method on the E-module has since been released, but was not available at the time of this study. The method was compared with an FDA-approved method for BNP, the active hormone that is produced in an equimolar ratio with NTproBNP. The clearance of these two molecules is di¡erent and thus the two hormones circulate at di¡erent concentrations particularly in patients with heart failure. 2 We were not able to include recent EQA data on within-method, between-laboratory comparability as there is no EQA scheme for NTproBNP, although such a scheme is in development. The question then arises as to what the EQA scheme will use as source of NTproBNP and whether the samples provided will truly mimic patient samples. Unfortunately, EQA is not the 'Gold Standard'. Quis custodies ipsos custodiet? 
SC Barnes and PO Collinson

Estimated GFR
The original article on estimated GFR by Lamb et al. dealt with a very important and topical issue. However, we feel that the statistical and graphical methods employed signi¢cantly take from the important message of this work. Unsurprisingly, the four creatinine data-sets had a non-Gaussian distribution, as should ideally be the case in method comparison studies. 2 For some unexplained reason, the authors then proceeded to log transform the data to produce a normal distribution. To the best of our knowledge, the only requirement before performing regression analysis is that the data exhibit a linear relationship. As a result, the regression data in Table 2 are meaningless as very few people can appreciate the signi¢cance of a slope or intercept that has been log transformed. Furthermore, the authors do not describe which version of linear regression was employed and, accordingly, we are unaware of whether the regression method used took into account any variation in the x-axis or not. When Bland and Altman described their di¡erence plot, 3 they made it clear that the data needed to exhibit a normal distribution before standard deviations (SDs) can be calculated. However, it is very clear from the second and third parts of Figure 1 that the data are not normally distributed and, accordingly, the related SD cut-o¡s in Figure 1 and the con¢-dence intervals in Table 2 are not valid. The correct di¡erence plot that should have been employed is the relative (also called percentage) di¡erence plot, as there is clearly an element of a proportional bias in the respective data.
To assess the signi¢cance of bias compared to the ID-MS method, the Wilcoxon's matched-pairs signedranks test was employed. This only compares the di¡er-ence between the medians 4 and, as a result, it is not surprising that the P-value for the bias with the Ja¡e method was not signi¢cant, as there appears to be no signi¢cant di¡erence at the median concentration. However, it is clear from Figure 1 that at low and high concentrations there is a bias of the order of 10 mmol/L. If a relative di¡erence plot and non-log-transformed Deming or Passing & Bablok were employed, we believe that the problems with the Ja¡e method may have been signi¢cant.
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